Article: Excipient Selection in Topical Process Development

This article is taken from Pharmaceutical Manufacturing and Packing Sourcer October 2023, pages 92-94. © Samedan Ltd

Unlike solid dosage drug products and sterile injectables, topical and transdermal formulations often contain a higher number of excipients, making them more complex to develop and scale. Given that the processes that can be used for manufacturing a drug product are largely impacted by the specific components of that product’s composition, a strong comprehension of the formulation is key.

Throughout drug product development, it is critical to understand the excipients, processing parameters, and quality attributes specific to the product so that optimal excipients and manufacturing methods can be established for future commercialization.

In this article with PMPS, MedPharm’s Head of Process Development, Joseph Holt, discusses the critical role that excipient selection plays in process development, and the importance of working with a reliable development partner.

Read the full article here.

About The Author

Joseph Holt joined MedPharm’s Formulation Development team in 2013 and now serves as the organization’s Head of Process Development. His expertise includes semi-solid product development, scale-up, and tech transfer. Holt has supported the development of more than 50 semi-solid and liquid products over the past decade, with many moving forward to commercialisation.

About MedPharm

MedPharm is a global contract provider of topical and transdermal formulation development services specializing in reducing risk through unique, cost-effective, and industry-leading performance testing models. MedPharm offers innovative dermal/transdermal, respiratory, mucosal membrane, ophthalmic, and ungual product development solutions with locations in the United Kingdom and the United States. For more information, visit or follow us on LinkedIn